Skip to main
PEPG

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform and pipeline products targeting severe neuromuscular and neurologic diseases. Management has reported positive preclinical results with its EDO peptides, demonstrating tissue penetration, cellular uptake, and nuclear delivery in a broad range of tissues, as well as encouraging safety and efficacy data from early-stage clinical trials. The company's potential to differentiate itself from competitors with its steric blocking mechanism and potential for significant market success make it a strong investment opportunity.

Bears say

PepGen is a clinical-stage biotechnology company with a promising technology platform, but the recent FREEDOM-2 data for their lead compound PGN-EDODM1 is difficult to interpret and raises some safety concerns. Additionally, the company may face challenges in commercializing their products and may need to seek external funding to advance their development. With uncertainties around the safety and efficacy of their compounds, coupled with potential competition in the market, the negative outlook for PepGen's stock is supported by these fundamental reasons.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Strong Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.